welcome
Benzinga

Benzinga

Health

Health

Sage Therapeutics stock is up 37.3% at $7.62 after Biogen offers $7.22 per share

Benzinga
Summary
Nutrition label

74% Informative

Sage Therapeutics Inc. (NASDAQ:SAGE) confirmed that Biogen Inc. submitted an unsolicited, nonbinding proposal to acquire all of the outstanding shares not already owned by Biogen for $ 7.22 per share.

The deal included an upfront payment of $875 million and a $650 million equity investment.

VR Score

67

Informative language

64

Neutral language

40

Article tone

formal

Language

English

Language complexity

56

Offensive language

not offensive

Hate speech

not hateful

Attention-grabbing headline

detected

Known propaganda techniques

not detected

Time-value

medium-lived

External references

11

https://www.benzinga.comhttps://www.benzinga.com/general/biotech/24/09/41049022/biogen-terminates-collaboration-with-sage-therapeutics-for-neurological-disorder-candidate?utm_campaign=partner_feed&utm_source=yahooFinance&utm_medium=partner_feed&utm_content=site&nid=42946734https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9spja3yaad1&utm_source=yahoohttps://www.benzinga.com/general/biotech/24/10/41382549/after-series-of-trial-setbacks-sage-therapeutics-to-lay-off-one-third-workforce?utm_campaign=partner_feed&utm_source=yahooFinance&utm_medium=partner_feed&utm_content=site&nid=42946734https://www.benzinga.com/25/01/42939868/asia-and-europe-markets-in-red-lower-crude-oil-gains-dollar-strengthens-global-markets-today-while-us-slept?utm_campaign=partner_feed&utm_source=yahooFinance&utm_medium=partner_feed&utm_content=site&nid=42946734https://www.benzinga.com/pressreleases/24/10/b41376682/sage-therapeutics-announces-strategic-reorganization-to-prioritize-zurzuvae-commercialization-and-?utm_campaign=partner_feed&utm_source=yahooFinance&utm_medium=partner_feed&utm_content=site&nid=42946734https://www.benzinga.com/pressreleases/25/01/b42930564/sage-therapeutics-confirms-receipt-of-unsolicited-nonbinding-acquisition-proposal-from-biogen?utm_campaign=partner_feed&utm_source=yahooFinance&utm_medium=partner_feed&utm_content=site&nid=42946734https://www.benzinga.com/quote/BIIB?getReport=1https://www.benzinga.com/25/01/42946734/why-is-depression-focused-sage-therapeutics-stock-surging-higher-on-mondayhttps://www.benzinga.com/24/11/42092122/after-failed-alzheimers-study-sage-therapeutics-dalzanemdor-flunks-another-study-in-patients-with-inherited-brain-disorder?utm_campaign=partner_feed&utm_source=yahooFinance&utm_medium=partner_feed&utm_content=site&nid=42946734https://investors.biogen.com/news-releases/news-release-details/biogen-and-sage-therapeutics-announce-global-collaboration

Affiliate links

no affiliate links